Tags

Type your tag names separated by a space and hit enter

Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.
Eur J Clin Pharmacol. 2014 Dec; 70(12):1433-41.EJ

Abstract

PURPOSE

Alterations in one-carbon metabolism (OCM) have been repeatedly reported in schizophrenia. However, there is a scarcity of studies addressing the effects of antipsychotics on selected OCM markers in schizophrenia and provided results are inconsistent.

METHODS

We recruited 39 first-episode schizophrenia (FES) patients and determined serum profile of total homocysteine (tHcy), folate, vitamin B12, lipoproteins and glucose at baseline and after 12 weeks of treatment with second-generation antipsychotics (SGA) including olanzapine and risperidone in monotherapy.

RESULTS

After 12 weeks of treatment, all patients had significantly higher body mass index (BMI), serum levels of total cholesterol (TC), low-density lipoproteins (LDL), triglycerides (TG) and tHcy together with significantly lower levels of folate and vitamin B12. The analysis of differences between SGA revealed the same biochemical alterations in patients treated with olanzapine as in the whole group, while those receiving risperidone had no statistically significant changes in serum folate, vitamin B12 and TG. There was a significantly higher increase in BMI and TC in patients treated with olanzapine in comparison with those treated with risperidone. Patients receiving olanzapine had a higher decrease in vitamin B12 than those assigned to the treatment with risperidone. Changes in folate, vitamin B12, tHcy and TC levels were significant only in males, even after Bonferroni correction. Multiple regression analysis revealed that changes in tHcy levels are associated with gender and baseline metabolic parameters (BMI, glucose, TC, LDL and HDL) but not with selected SGA.

CONCLUSIONS

These results indicate that SGA may influence OCM, especially in first-episode schizophrenia (FES) males.

Authors+Show Affiliations

Department of Psychiatry, Wroclaw Medical University, 10 Pasteur Street, 50-367, Wroclaw, Poland, mblazej@interia.eu.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Journal Article
Observational Study
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

25291992

Citation

Misiak, Błażej, et al. "Effects of Second-generation Antipsychotics On Selected Markers of One-carbon Metabolism and Metabolic Syndrome Components in First-episode Schizophrenia Patients." European Journal of Clinical Pharmacology, vol. 70, no. 12, 2014, pp. 1433-41.
Misiak B, Frydecka D, Łaczmański Ł, et al. Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. Eur J Clin Pharmacol. 2014;70(12):1433-41.
Misiak, B., Frydecka, D., Łaczmański, Ł., Ślęzak, R., & Kiejna, A. (2014). Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. European Journal of Clinical Pharmacology, 70(12), 1433-41. https://doi.org/10.1007/s00228-014-1762-2
Misiak B, et al. Effects of Second-generation Antipsychotics On Selected Markers of One-carbon Metabolism and Metabolic Syndrome Components in First-episode Schizophrenia Patients. Eur J Clin Pharmacol. 2014;70(12):1433-41. PubMed PMID: 25291992.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients. AU - Misiak,Błażej, AU - Frydecka,Dorota, AU - Łaczmański,Łukasz, AU - Ślęzak,Ryszard, AU - Kiejna,Andrzej, Y1 - 2014/10/08/ PY - 2014/07/31/received PY - 2014/09/26/accepted PY - 2014/10/9/entrez PY - 2014/10/9/pubmed PY - 2015/7/7/medline SP - 1433 EP - 41 JF - European journal of clinical pharmacology JO - Eur. J. Clin. Pharmacol. VL - 70 IS - 12 N2 - PURPOSE: Alterations in one-carbon metabolism (OCM) have been repeatedly reported in schizophrenia. However, there is a scarcity of studies addressing the effects of antipsychotics on selected OCM markers in schizophrenia and provided results are inconsistent. METHODS: We recruited 39 first-episode schizophrenia (FES) patients and determined serum profile of total homocysteine (tHcy), folate, vitamin B12, lipoproteins and glucose at baseline and after 12 weeks of treatment with second-generation antipsychotics (SGA) including olanzapine and risperidone in monotherapy. RESULTS: After 12 weeks of treatment, all patients had significantly higher body mass index (BMI), serum levels of total cholesterol (TC), low-density lipoproteins (LDL), triglycerides (TG) and tHcy together with significantly lower levels of folate and vitamin B12. The analysis of differences between SGA revealed the same biochemical alterations in patients treated with olanzapine as in the whole group, while those receiving risperidone had no statistically significant changes in serum folate, vitamin B12 and TG. There was a significantly higher increase in BMI and TC in patients treated with olanzapine in comparison with those treated with risperidone. Patients receiving olanzapine had a higher decrease in vitamin B12 than those assigned to the treatment with risperidone. Changes in folate, vitamin B12, tHcy and TC levels were significant only in males, even after Bonferroni correction. Multiple regression analysis revealed that changes in tHcy levels are associated with gender and baseline metabolic parameters (BMI, glucose, TC, LDL and HDL) but not with selected SGA. CONCLUSIONS: These results indicate that SGA may influence OCM, especially in first-episode schizophrenia (FES) males. SN - 1432-1041 UR - https://www.unboundmedicine.com/medline/citation/25291992/Effects_of_second_generation_antipsychotics_on_selected_markers_of_one_carbon_metabolism_and_metabolic_syndrome_components_in_first_episode_schizophrenia_patients_ L2 - https://dx.doi.org/10.1007/s00228-014-1762-2 DB - PRIME DP - Unbound Medicine ER -